{
  "id": 523978,
  "title": "SK Bioscience narrows loss in Q2 upon German unit's improvement",
  "url": "https://urgent.news/2026/08/11/sk-bioscience-narrows-loss-in-q2-upon-german-units-improvement",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-11T02:42:02.000Z",
  "source": {
    "name": "The Korea Times",
    "slug": "the-korea-times",
    "url": "https://www.koreatimes.co.kr/business/companies/20260811/sk-bioscience-narrows-loss-in-q2-upon-german-units-improvement"
  },
  "original_language": "en",
  "account": "SK Bioscience, a vaccine specialist, reported a narrowing of its operating loss in the second quarter of 2024. The company's revenue fell by 3.8% compared to the same period in the previous year, reaching 155.7 billion won ($110 million). However, its operating loss dropped significantly to 15.7 billion won from 37.4 billion won. The decline in revenue was attributed to a temporary delay in the supply schedule for some of the company's vaccines. The shipments were pushed back to the third quarter, and the impact on the full-year performance was expected to be minimized. SK Bioscience's profitability improvement was largely attributed to IDT Biologika, a German contract development and manufacturing organization (CDMO) that the company acquired in 2024. IDT Biologika's earnings improved as production volumes increased for major clients, while costs declined due to workforce optimization and higher production yields.",
  "summary": "SK Bioscience, a vaccine specialist, reported a narrowing of its operating loss in the second quarter, driven by the improvement of its German subsidiary, IDT Biologika. The company's revenue for the April-June period stood at 155.7 billion won ($110 million), a 3.8 percent decrease from the previous year. However, its operating loss narrowed to 15.7 billion won from 37.4 billion won in the same period. The slight decline in revenue was attributed to a temporary delay in the supply schedule for some of its vaccines, with the impact expected to be limited in the full-year performance. IDT Biologika's earnings improved due to increased production volumes for major clients and cost reductions through workforce optimization and higher production efficiency.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "The Korea Times",
        "title": "SK Bioscience narrows loss in Q2 upon German unit's improvement",
        "url": "https://urgent.news/2026/08/11/sk-bioscience-narrows-loss-in-q2-upon-german-units-improvement-524857",
        "published": "2026-08-11T02:57:02.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}